Beam Therapeutics Inc
BEAM
$21.60
Closing
▼-5.01%
1D
▼-20.65%
YTD
Market cap
$1.78B
52 week high
$49.49
52 week low
$16.99
Volume
543,806
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$1.78B
Analysts' Rating
BUY
Price Target (Mean)
53.69231
Total Analysts
14
P/E
Operating Margin
-629.72%
Beta
1.87
Revenue Growth (Annual)
17.51%
52 week high
$49.49
52 week low
$16.99
Div. Yield
%
EPS Annual Growth
12.96
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Beam Therapeutics Inc. is a biotechnology company engaged in providing life-long cures to patients suffering from serious diseases. The Company operates a fully integrated platform for precision genetic medicines. Its base editing technology enables a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). The Company is advancing its base editing technology across three disease-area portfolios: hematology, immunology/oncology and genetic diseases. Its clinical-stage programs include BEAM-101, BEAM-201, BEAM-301 and BEAM-302. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy designed to offer a profile, incorporating base edits that are intended to mimic single nucleotide polymorphisms seen in individuals with hereditary persistence of fetal hemoglobin (HPFH). BEAM-201 is a development candidate comprised of T cells.
